Theriva Biologics
TOVX
70 hedge funds and large institutions have $34M invested in Theriva Biologics in 2016 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 21 increasing their positions, 9 reducing their positions, and 9 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 9
122% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 9
17% more funds holding
Funds holding: 60 → 70 (+10)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
44% less capital invested
Capital invested by funds: $60.8M → $34M (-$26.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$5.38M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$3.56M |
| 3 |
MP
MSD Partners
New York
|
+$1.18M |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$1.17M |
| 5 |
Millennium Management
New York
|
+$883K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$1.99M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.14M |
| 3 |
William Blair & Company
Chicago,
Illinois
|
-$411K |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$131K |
| 5 |
RCP
Rothschild Capital Partners
New York
|
-$52K |
TOVX Hedge Fund Activity: Q4 2016 in Review
70 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q4 2016, worth a combined $34M — down 44% from $60.8M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new TOVX positions and 9 closed out — a net gain of 11 holders — while 21 added to existing stakes and 9 trimmed.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $5.38M. The largest seller was Knoll Capital Management, cutting an estimated $1.99M.
- 70 institutional investors held Theriva Biologics (TOVX) as of Q4 2016, up from 60 in Q3 2016.
- Funds reported $34M of Theriva Biologics stock for Q4 2016, down 44% quarter-over-quarter.
- 20 funds opened new Theriva Biologics positions in Q4 2016 and 9 closed out, a net change of +11 holders.
- The largest Theriva Biologics buyer in Q4 2016 was Alyeska Investment Group, an estimated $5.38M added.
- The largest Theriva Biologics seller in Q4 2016 was Knoll Capital Management, an estimated $1.99M sold.
Based on aggregated 13F filings for Q4 2016.